J&J to buy cardio technology company Abiomed for $16.6 billion


J&J to buy cardio technology company Abiomed for $16.6 billion

Johnson & Johnson is spending more than $16 billion to move deeper into treating heart disease and continue a shift started last year away from its consumer health roots.

The health care giant said that it will buy the cardiovascular technology company Abiomed, which makes a heart pump used in patients with severe coronary artery disease.

The deal is expected to close early next year and will bolster J&J‘s MedTech, or medical device, division. That’s one of two remaining segments, along with pharmaceuticals, that the company is focused on after announcing that it would split off its consumer health division that sells Band Aids and beauty products.

Read Also

India e-logistics industry set to touch 9 billion with e-commerce boom
Self-driving cars face uncertain path to US deployment

The deal for Danvers, Massachusetts-based Abiomed will complement J&J’s existing heart business and comes with “significant” expansion opportunities, CEO Joaquin Duato told analysts during a conference call.

It also adds to J&J’s portfolio a company with explosive growth. Abiomed’s sales jumped 22 percent to exceed $1 billion in its most recent fiscal year. That is well over twice the annual sales it had booked just five years ago.

J&J’s BioSense business focuses on treating arrhythmia, or an irregular heartbeat. Abiomed will add, among other products, its Impella heart pumps, which are inserted through arteries into the hearts of high-risk patients. They temporarily help the heart maintain blood flow while a surgeon places stents in the patient.

Abiomed will run as a stand-alone business within J&J’s medical device segment once the deal is completed.

J&J said it will pay $380 in cash for each Abiomed share. It will also throw in another $35 per share in cash if some commercial and clinical milestones are met in the next few years.

J&J will pay for the deal with a combination of cash and short-term financing. The company expects the acquisition to be neutral or to slightly dilute adjusted earnings in the first year after its completion. It then expects that the deal will help its bottom line starting in 2024.

The deal comes a few weeks after J&J said it topped third-quarter expectations, thanks to growth from its largest segment, pharmaceuticals. Sales climbed 2 percent in the company’s medical device segment, to $6.78 billion.

Shares of Johnson & Johnson, based in New Brunswick, New Jersey, slipped nearly a dollar to $173.11 in Tuesday morning trading. The Dow Jones Industrial Average, of which J&J is a component, rose slightly.

Shares of Abiomed Inc. soared more than 50 percent to $380.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *